MODD

- Council to Provide Strategic Clinical Guidance on Commercialization, Patient Identification, Workflow Integration, and Evidence Generation SAN DIEGO, CA / ACCESS Newswire / July 23, 2026 / Modular Medical, Inc, ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company's clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council.

Pilot Combines Clinician Guided Phenotypes with IMO Health's Unique Terminology Identifiers to Help Clinicians Easily Identify Patients Most Likely to Benefit from Pivot Insulin Pump Therapy Advancing Towards Fourth Quarter Commercial Launch of Pivot Pump SAN DIEGO, CA AND ROSEMONT, IL / ACCESS Newswire / July 16, 2026 / Modular Medical, Inc., ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today announced an important pilot collaboration with IMO Health, whose expert-curated clinical terminology and accountable healthcare AI solutions are used across nearly all U.S. health systems to transform healthcare data into trusted clinical context. Through this pilot, Modular Medical and IMO Health expect to develop a deployable terminology-powered phenotypic algorithm designed to identify diabetes patients who may benefit from insulin pump therapy directly within the electronic health record (EHR).

Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot SAN DIEGO, CA / ACCESS Newswire / July 15, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel. "From the earliest stages of development, our goal has been to develop a practical and affordable insulin pumping solution that removes many of the barriers preventing insulin-dependent individuals from transitioning from multiple daily injections to pump therapy," said Jeb Besser, CEO of Modular Medical.

97% of Surveyed Injection Users Would Consider Pump Therapy - if Easier to Learn and Improved Outcomes Conducting Additional Research Initiative in Conjunction with Commercialization of the Pivot Tubeless Insulin Patch Pump Company to Showcase Pivot at Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, August 7-10, 2026 SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026.

Submission Covers Software Enhancements for Patient Flexibility and Customization of Pivot SAN DIEGO, CA / ACCESS Newswire / July 1, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced submission to the U.S. Food & Drug Administration (FDA) of a series of software enhancements to its PivotTM insulin delivery system, providing users with more customization options and user-interface (UI) improvements, as well as other software upgrades. "This submission is the first of a series of further improvements and upgrades planned for the Pivot platform, now that our core form factor has been cleared by the FDA and is in the market.

First Patients Began Device Training and Insulin Delivery Today, Marking Transition to a Commercial Company Pivot is the First Insulin Pump Designed to Address the Large, Underserved Population of Insulin-Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion-Dollar Market SAN DIEGO, CO / ACCESS Newswire / June 30, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical's commercialization strategy.

Pivot starter kits are now shipping to multiple endocrinology practices SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks.

The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April Pivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar market Commercial expansion activities are expected to begin in Q4 2026 SAN DIEGO, CA / ACCESS Newswire / June 24, 2026 / Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company's transition to a commercial-stage medical device company.

Initial patients expected in June 2026 SAN DIEGO, CA / ACCESS Newswire / June 4, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company's receipt of U.S. Food and Drug Administration ("FDA") clearance in April 2026 for its Pivot™ insulin delivery system.

Meet with Modular Medical CEO Jeb Besser There are 4.8 million individuals with diabetes in the US that require daily insulin. Only 20% currently use an insulin pump.